Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial (Q33401179)

26 July 2017

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial (English)

1 reference

26 July 2017

phase III clinical trial

0 references

0 references

1 reference

1 reference

1 reference

Ghazaleh Tabatabai

5

0 references

Michael Platten

object named as

Michael Platten

2

0 references

Michael Weller

18

object named as

Michael Weller

1 reference

26 July 2017

1

Wolfgang Wick

1 reference

26 July 2017

17

Guido Reifenberger

1 reference

26 July 2017

4

Jörg Felsberg

1 reference

26 July 2017

14

Jürgen Meixensberger

1 reference

26 July 2017

10

Michael Sabel

1 reference

26 July 2017

7

Guido Nikkhah

1 reference

26 July 2017

8

Kirsten Papsdorf

1 reference

26 July 2017

9

Joachim P Steinbach

1 reference

26 July 2017

15

Ralf Ketter

1 reference

26 July 2017

Regine Mayer-Steinacker

16

object named as

Regine Mayer-Steinacker

1 reference

26 July 2017

11

Stephanie E Combs

0 references

author name string

Christoph Meisner

3

1 reference

26 July 2017

Matthias Simon

6

1 reference

26 July 2017

Jan Vesper

12

1 reference

26 July 2017

Christian Braun

13

1 reference

26 July 2017

NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society

19

1 reference

26 July 2017

10 May 2012

1 reference

Lancet Oncology Commission

26 July 2017

1 reference

26 July 2017

13

1 reference

26 July 2017

7

1 reference

26 July 2017

707-715

1 reference

Geriatric neuro-oncology: from mythology to biology

26 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970164-X

7 January 2021

Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970164-X

7 January 2021

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970164-X

7 January 2021

Radiotherapy for glioblastoma in the elderly.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970164-X

7 January 2021

Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970164-X

7 January 2021

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970164-X

7 January 2021

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970164-X

7 January 2021

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970164-X

7 January 2021

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970164-X

7 January 2021

Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970164-X

7 January 2021

Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970164-X

7 January 2021

Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970164-X

7 January 2021

One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970164-X

7 January 2021

The 2007 WHO classification of tumours of the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970164-X

7 January 2021

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970164-X

7 January 2021

Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970164-X

7 January 2021

Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970164-X

7 January 2021

A log-rank test for equivalence of two survivor functions.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970164-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970164-X

7 January 2021

Longitudinal Data with Follow-up Truncated by Death: Match the Analysis Method to Research Aims

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970164-X

7 January 2021

Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970164-X

7 January 2021

Patterns of care in elderly glioblastoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970164-X

7 January 2021

Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970164-X

7 January 2021

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970164-X

7 January 2021

A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970164-X

7 January 2021

10.1016/S1470-2045(12)70164-X

Identifiers

DOI

1 reference

26 July 2017

1 reference